Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.40 -5.76%

-$0.10 today

Market cap
$97.62M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 6.81M

Average 17.46M

Income Statement

Follow revenue through to earnings.

Revenue

$1.41M

FY 2025 · Annual

Operating Income

-$67.06M

FY 2025 · Annual

Net Income

-$62.42M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Sep 2021
FY 2022
Sep 2022
FY 2023
Sep 2023
FY 2024
Sep 2024
FY 2025
Sep 2025
Revenue00001.41M
Cost of Revenue262.14K204.69K44.19K113.86K756.33K
Gross Profit(262.14K)(204.69K)(44.19K)(113.86K)657.21K
Gross Margin————46.5%
Research & Development38.96M42.33M26.45M41.76M27.18T
Selling, General & Admin12.77M20.74M26.67M29.94M39.94M
Operating Expenses51.73M62.87M53.13M71.7M67.72M
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
EBITDA(51.51M)(64.36M)(57.38M)(72.09M)(63.58M)
EBITDA Margin————-4497.7%
Operating Income(51.73M)(63.07M)(53.13M)(71.7M)(67.06M)
Operating Margin————-4744.3%
Interest Income000906.15K89.74K
Interest Expense936.13K1.49M1.56M3.16M283.13K
Other Income / Expenses(1.43M)(2.98M)(5.85M)(3.66M)3.08M
Income Before Tax(53.16M)(66.05M)(58.98M)(75.36M)(63.98M)
Pre-Tax Margin————-4526.0%
Income Tax Expense2K2.8K2.8K2.8K(1.55M)
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Net Margin————-4416.2%
EPS (Basic)(6.96)(6.23)(4.72)(4.06)(1.79)
EPS (Diluted)(6.96)(6.23)(4.72)(4.06)(1.79)
Weighted Avg Shares7.63M10.6M12.51M18.55M34.8M
Weighted Avg Shares (Diluted)7.63M10.6M12.51M18.55M25.48M

OTLK Earnings Waterfall · TTM

NASDAQ:OTLK · Revenue to Net Income

Key Ratios

EPS$-1.62
Gross Margin313.6%
Net Margin2889.6%
P/E Ratio-0.9
P/S Ratio-77.3

Analysis

$333.1K of revenue converted into -$61.0M of net income for the selected period. Gross margin is 313.6% and net margin is 2889.6%, showing how much revenue survives after costs and taxes. EPS is $-1.62, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingOct 13, 2026
8-KCurrent reportSep 30, 2026
8-KCurrent reportSep 18, 2026
4Statement of changes in beneficial ownershipSep 2, 2026
3Initial statement of beneficial ownershipSep 2, 2026

How much revenue does OTLK generate?

Outlook Therapeutics, Inc. (OTLK) reported $1.41M of revenue in fiscal 2025.

Is OTLK profitable?

Outlook Therapeutics, Inc. (OTLK) reported -$62.42M of net income, with a net margin of -4416.2%.